Edition:
United States

Sierra Oncology Inc (SRRA.OQ)

SRRA.OQ on NASDAQ Stock Exchange Global Market

2.57USD
4:00pm EDT
Change (% chg)

$-0.05 (-1.91%)
Prev Close
$2.62
Open
$2.62
Day's High
$2.68
Day's Low
$2.49
Volume
79,004
Avg. Vol
97,611
52-wk High
$4.09
52-wk Low
$1.11

Chart for

About

Sierra Oncology, Inc., formerly ProNAi Therapeutics, Inc., is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response... (more)

Overall

Beta: --
Market Cap(Mil.): $207.33
Shares Outstanding(Mil.): 74.31
Dividend: --
Yield (%): --

Financials

  SRRA.OQ Industry Sector
P/E (TTM): -- 223.30 32.53
EPS (TTM): -0.65 -- --
ROI: -27.98 -8.07 12.63
ROE: -27.98 -10.87 14.50

BRIEF-Sierra Oncology Reports Qtrly Loss Per Share $0.19

* SIERRA ONCOLOGY INC - SRA737 MONOTHERAPY PHASE 1/2 TRIAL EXPANDED TO ENROLL CCNE1-DRIVEN OVARIAN CANCER COHORT

May 10 2018

BRIEF-Sierra Oncology Announces Pricing Of Public Offering Of Common Stock

* SIERRA ONCOLOGY ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

Mar 02 2018

BRIEF-Sierra Oncology Announces Proposed Public Offering Of Common Stock

* SIERRA ONCOLOGY ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

Mar 01 2018

BRIEF-Sierra Oncology Significantly Expands Clinical Development Program

* SIERRA ONCOLOGY SIGNIFICANTLY EXPANDS CLINICAL DEVELOPMENT PROGRAM

Feb 27 2018

BRIEF-Sierra Oncology Reports Qtrly Loss Of $0.20 Per Share

* SIERRA ONCOLOGY INC - QTRLY NET LOSS PER SHARE, BASIC AND DILUTED $0.20‍​

Feb 27 2018

Earnings vs. Estimates